- Email: [email protected]
Fresenius to distribute products from Advanced Renal Technologies
NEWS
Fresenius to distribute products from Advanced Renal Technologies
F
resenius Medical Care North America, a major provider of renal dialysis products and services, is to distribute Advanced Renal Technologies Inc’s dialysate products in the USA. The company and its subsidiary Fresenius USA Marketing Inc (FUSA) have signed an agreement with Advanced Renal Technologies that grants US supply and distribution rights to FUSA for Citrasate and Dryalysate, citrate dialysate used in haemodialysis for patients with end-stage renal disease (ESRD). Dialysate is used during haemodialysis. The bi-directional movement of molecules between blood and dialysate across a semi-permeable membrane (dialyser) removes toxins and wastes from the bloodstream while instilling the patient with valuable replacement molecules such as bicarbonate. Citrasate uses citric acid, a known anticoagulant, rather than traditional acetic acid, to regulate dialysate pH. Unlike traditional acetic acid, citric acid may provide a local anticoagulant effect at the dialysis membrane during haemodialysis. Initial clinical findings suggest a decreased usage of heparin anticoagulant therapy during haemodialysis with citrate dialysate, as well as an increased delivered dialysis dose. ‘We constantly strive to provide our renal partners with products and services that provide intradialytic enhancements. Citrasate and Dryalysate may further provide medical benefits and cost-savings by reducing the amount of heparin used for anticoagulation. We believe that working with Advanced Renal Technologies to supply a citrate dialysate to the industry is an important step to providing the market with products that may have a superior clinical benefit to traditional therapies used today,’ commented Rice Powell, Chief Executive Officer of Fresenius Medical Care North America. ‘Currently, Citrasate is mostly used by nurses and nephrologists in the acute market where little to no utilisation of heparin is the therapeutic preference,’ stated Michael Fulton, President of Advanced Renal Technologies. ‘This agreement will provide nephrologists with access to this product when prescribing treatment to patients in chronic haemodialysis facilities nationwide. Many ESRD patients, including those with heparin antibodies and heparin-induced thrombocytopenia, will benefit from Citrasate.’ 4
Membrane Technology
Operational and distribution planning is currently under way throughout Fresenius Medical Care’s Renal Products Division to increase product availability nationwide and set a competitive pricing structure for chronic dialysis applications. Contacts: Fresenius Medical Care North America, 920 Winter Street, Waltham, MA 02451-1457, USA. Tel: +1 781 699 9000, www.fmcna.com Fresenius Medical Care Ag & Co KGaA, Else-Kröner-Str. 1, D-61352 Bad Homburg, Germany. Tel: + 49 6172 609 2601, www.fmc-ag.com Advanced Renal Technologies Inc, 40 Lake Bellevue Drive, Suite 100, Bellevue, WA 98005, USA. Tel: +1 425 453 8777, www.citrasate.com
VWS honoured with two awards from Frost & Sullivan
F
rost & Sullivan has conferred two prestigious awards on French water treatment company Veolia Water Solutions & Technologies (VWS). The 2008 Frost & Sullivan European Pharmaceutical Water & Wastewater Treatment Business Development Strategy Leadership Award, lauds VWS for its successful strategies that have enabled it to consolidate its position as one of the leading process water and wastewater technology providers for the pharmaceutical industry in Europe. The 2008 Frost & Sullivan CEO of the Year Award in the Global Water and Wastewater Treatment Technology Market was presented to Jean Michel Herrewyn for his stellar role in steering this growth. ‘The success of VWS in the highly processcritical pharmaceutical industry is attributed to its well structured business strategies that centre on customised treatment technologies and comprehensive, fully integrated treatment systems and services,’ noted Frost & Sullivan research analyst Karthikeyan Ravikumar. Since 2005, VWS has also been successful in offering turnkey systems on a global basis to the pharmaceutical industry. Specific products include Orion, Quattro, Triton and Polaris for producing purified water and water for injection. The company also offers two after-sales services – Aquatrend and Aquamove. With Herrewyn at the helm, the company has successfully shifted from an approach based on market segments (which involved the division of the water industry into municipal, industrial water and industrial wastewater treat-
ment segments) to one that focuses on water and wastewater treatment technologies, says Frost & Sullivan. Another initiative undertaken during the tenure of Herrewyn has been the development of centres of excellence, especially among subsidiaries. This enterprise has already materialised with dedicated centres of excellence for key sectors such as the food and beverage, and pharmaceuticals industries. Lately, the firm has adopted a more discerning approach to treatment technologies. It is currently equipped with a strong portfolio of thermal desalination systems. ‘This complements the reverse osmosis (RO) membrane capabilities built up within VWS, resulting in aggressive growth in the desalination plant market in the Middle East,’ commented Frost & Sullivan research analyst Fredrick Harry Royan. Contacts: Frost & Sullivan, 4 Grosvenor Gardens, London SW1W 0DH, UK. Tel: +44 20 7730 3438. www.frost.com Frost & Sullivan, 7550 West Interstate 10, Suite 400, San Antonio, TX 78229-5616, USA. Tel: +1 877 463 7678 Veolia Water Solutions & Technologies, L’Aquarène, 1 place Montgolfier, 94417 Saint Maurice Cedex, France. Tel: +33 1 4511 5555, www.veoliawaterst.com
PWN establishes company to promote its technology
P
WN Water Supply Company NorthHolland recently launched a new international company – called PWN Technologies – that aims to make its technology, operational expertise and water treatment system designs available to fellow water companies all over the world for the provision of pure, clean water. PWN says that its achievements in supporting and promoting water treatment practices over the last decade are somewhat unknown. Its expertise has been employed primarily in its own facilities – though a great many water professionals in the world will have already come across PWN technologies without realising it. According to the company, examples include the world’s first wide-scale use of membranes for drinking-water treatment, the invention of UV hydrogen peroxide treatment, and pioneering work in the economic application of ceramic membranes for water treatment. Martien den Blanken, Executive Director
September 2009
Fresenius to distribute products from Advanced Renal Technologies
F
resenius Medical Care North America, a major provider of renal dialysis products and services, is to distribute Advanced Renal Technologies Inc’s dialysate products in the USA. The company and its subsidiary Fresenius USA Marketing Inc (FUSA) have signed an agreement with Advanced Renal Technologies that grants US supply and distribution rights to FUSA for Citrasate and Dryalysate, citrate dialysate used in haemodialysis for patients with end-stage renal disease (ESRD). Dialysate is used during haemodialysis. The bi-directional movement of molecules between blood and dialysate across a semi-permeable membrane (dialyser) removes toxins and wastes from the bloodstream while instilling the patient with valuable replacement molecules such as bicarbonate. Citrasate uses citric acid, a known anticoagulant, rather than traditional acetic acid, to regulate dialysate pH. Unlike traditional acetic acid, citric acid may provide a local anticoagulant effect at the dialysis membrane during haemodialysis. Initial clinical findings suggest a decreased usage of heparin anticoagulant therapy during haemodialysis with citrate dialysate, as well as an increased delivered dialysis dose. ‘We constantly strive to provide our renal partners with products and services that provide intradialytic enhancements. Citrasate and Dryalysate may further provide medical benefits and cost-savings by reducing the amount of heparin used for anticoagulation. We believe that working with Advanced Renal Technologies to supply a citrate dialysate to the industry is an important step to providing the market with products that may have a superior clinical benefit to traditional therapies used today,’ commented Rice Powell, Chief Executive Officer of Fresenius Medical Care North America. ‘Currently, Citrasate is mostly used by nurses and nephrologists in the acute market where little to no utilisation of heparin is the therapeutic preference,’ stated Michael Fulton, President of Advanced Renal Technologies. ‘This agreement will provide nephrologists with access to this product when prescribing treatment to patients in chronic haemodialysis facilities nationwide. Many ESRD patients, including those with heparin antibodies and heparin-induced thrombocytopenia, will benefit from Citrasate.’ 4
Membrane Technology
Operational and distribution planning is currently under way throughout Fresenius Medical Care’s Renal Products Division to increase product availability nationwide and set a competitive pricing structure for chronic dialysis applications. Contacts: Fresenius Medical Care North America, 920 Winter Street, Waltham, MA 02451-1457, USA. Tel: +1 781 699 9000, www.fmcna.com Fresenius Medical Care Ag & Co KGaA, Else-Kröner-Str. 1, D-61352 Bad Homburg, Germany. Tel: + 49 6172 609 2601, www.fmc-ag.com Advanced Renal Technologies Inc, 40 Lake Bellevue Drive, Suite 100, Bellevue, WA 98005, USA. Tel: +1 425 453 8777, www.citrasate.com
VWS honoured with two awards from Frost & Sullivan
F
rost & Sullivan has conferred two prestigious awards on French water treatment company Veolia Water Solutions & Technologies (VWS). The 2008 Frost & Sullivan European Pharmaceutical Water & Wastewater Treatment Business Development Strategy Leadership Award, lauds VWS for its successful strategies that have enabled it to consolidate its position as one of the leading process water and wastewater technology providers for the pharmaceutical industry in Europe. The 2008 Frost & Sullivan CEO of the Year Award in the Global Water and Wastewater Treatment Technology Market was presented to Jean Michel Herrewyn for his stellar role in steering this growth. ‘The success of VWS in the highly processcritical pharmaceutical industry is attributed to its well structured business strategies that centre on customised treatment technologies and comprehensive, fully integrated treatment systems and services,’ noted Frost & Sullivan research analyst Karthikeyan Ravikumar. Since 2005, VWS has also been successful in offering turnkey systems on a global basis to the pharmaceutical industry. Specific products include Orion, Quattro, Triton and Polaris for producing purified water and water for injection. The company also offers two after-sales services – Aquatrend and Aquamove. With Herrewyn at the helm, the company has successfully shifted from an approach based on market segments (which involved the division of the water industry into municipal, industrial water and industrial wastewater treat-
ment segments) to one that focuses on water and wastewater treatment technologies, says Frost & Sullivan. Another initiative undertaken during the tenure of Herrewyn has been the development of centres of excellence, especially among subsidiaries. This enterprise has already materialised with dedicated centres of excellence for key sectors such as the food and beverage, and pharmaceuticals industries. Lately, the firm has adopted a more discerning approach to treatment technologies. It is currently equipped with a strong portfolio of thermal desalination systems. ‘This complements the reverse osmosis (RO) membrane capabilities built up within VWS, resulting in aggressive growth in the desalination plant market in the Middle East,’ commented Frost & Sullivan research analyst Fredrick Harry Royan. Contacts: Frost & Sullivan, 4 Grosvenor Gardens, London SW1W 0DH, UK. Tel: +44 20 7730 3438. www.frost.com Frost & Sullivan, 7550 West Interstate 10, Suite 400, San Antonio, TX 78229-5616, USA. Tel: +1 877 463 7678 Veolia Water Solutions & Technologies, L’Aquarène, 1 place Montgolfier, 94417 Saint Maurice Cedex, France. Tel: +33 1 4511 5555, www.veoliawaterst.com
PWN establishes company to promote its technology
P
WN Water Supply Company NorthHolland recently launched a new international company – called PWN Technologies – that aims to make its technology, operational expertise and water treatment system designs available to fellow water companies all over the world for the provision of pure, clean water. PWN says that its achievements in supporting and promoting water treatment practices over the last decade are somewhat unknown. Its expertise has been employed primarily in its own facilities – though a great many water professionals in the world will have already come across PWN technologies without realising it. According to the company, examples include the world’s first wide-scale use of membranes for drinking-water treatment, the invention of UV hydrogen peroxide treatment, and pioneering work in the economic application of ceramic membranes for water treatment. Martien den Blanken, Executive Director
September 2009